Autolus Therapeutics PLC (AUTL)
3.345
-0.16
(-4.43%)
USD |
NASDAQ |
Nov 04, 16:00
3.345
0.00 (0.00%)
After-Hours: 20:00
Autolus Therapeutics Research and Development Expense (Annual): 130.48M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 130.48M |
| December 31, 2022 | 117.35M |
| December 31, 2021 | 110.84M |
| December 31, 2020 | 134.89M |
| December 31, 2019 | 105.42M |
| Date | Value |
|---|---|
| December 31, 2018 | 17.71M |
| September 30, 2018 | 36.15M |
| September 30, 2017 | 16.01M |
| September 30, 2016 | 10.44M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
105.42M
Minimum
2019
134.89M
Maximum
2020
119.80M
Average
117.35M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Adaptimmune Therapeutics PLC | 126.51M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | 31.19M |
| TC BioPharm (Holdings) PLC | 9.670M |
| Verona Pharma PLC | 17.22M |